What kind of kidney injury does Linvoseltamab cause?

Prerenal / Hemodynamic AKI — Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome. Other reported patterns: Crystal / Obstructive Nephropathy, Electrolyte Disturbance.

How should kidney function be monitored during Linvoseltamab therapy?

Serial serum creatinine/eGFR through step-up dosing and the first cycles; CRS grading (temperature, blood pressure, oxygenation); Tumor lysis labs (uric acid, phosphate, potassium, calcium, LDH) at initiation in high-burden disease; Electrolytes (K, Mg, PO4) during CRS and supportive care; Volume status and urine output; Infection surveillance given high infection rates in this class.

How can kidney injury from Linvoseltamab be prevented?

Mandatory step-up (split) dosing to blunt CRS severity Pre-medication (corticosteroid, antihistamine, antipyretic) per label during step-up Prompt tocilizumab ± steroids at CRS onset; prophylactic tocilizumab reduces CRS in real-world cohorts Adequate hydration and avoidance of volume depletion around dosing TLS prophylaxis (hydration, allopurinol/rasburicase) in high-burden disease Treat/avoid concurrent infection; minimize nephrotoxin and contrast exposure Optimize myeloma-related kidney burden (hypercalcemia, light chains)

Who is at higher risk of kidney injury from Linvoseltamab?

Higher-grade cytokine release syndrome (Grade ≥2); Pre-existing chronic kidney disease; High myeloma burden / risk of tumor lysis (elevated bone-marrow plasma cells, soluble BCMA); Concurrent infection or sepsis; Volume depletion / hypotension; Light-chain cast nephropathy and hypercalcemia from underlying myeloma; Nephrotoxic co-medications and contrast exposure.

Back to explorer

Printable monograph

BCMA×CD3 bispecific T-cell engager

Linvoseltamab

Lynozyfic · BCMA×CD3 engager

BCMA×CD3 bispecific T-cell engager · approved 2025 · 6 citations

Up to date· through 2025

Fairly sourced5/9 · 5 signals

Met: 6 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 1y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

T-cell redirection, not tubular poison — AKI rides on cytokine release, not the drug itself.

MildBCMA T-cell-redirection era (2022 onward)

Relapsed/refractory multiple myeloma after ≥3-4 prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody

§01

Signature kidney injury

Signature lesion

Prerenal / Hemodynamic AKI

No drug-specific renal toxicity signal was reported in the LINKER-MM1 registrational program; AKI is not a labeled or characteristic adverse event. Any kidney injury is expected to be indirect and infrequent, mediated chiefly by cytokine release syndrome (CRS), infection/sepsis, and (early) tumor lysis. By class analogy to CAR-T and other immune-effector therapies, AKI occurs in roughly 5-21% of T-cell-redirection recipients, is usually mild (KDIGO stage 1) and transient with recovery in ~79% within a month, and tracks with higher-grade CRS. No linvoseltamab-specific incidence is published.Source: No linvoseltamab-specific renal incidence reported in LINKER-MM1 (Bumma 2024, PMID 38879802; Lee 2025, PMID 41387038). Class-level AKI estimates (~5-21%, mostly transient, CRS-associated) extrapolated from CAR-T/immune-effector cohorts (León-Román 2024, PMID 38500492; Rousseau 2024, PMID 36220698).

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Days — coincident with step-up dosing and CRS in the first 1–2 weeks.

Distilled from: “Days — coincident with step-up dosing and CRS in the first 1-2 weeks; CRS in LINKER-MM1 occurred predominantly during step-up dosing.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Crystal / Obstructive NephropathySecondaryqualitative — no citable incidence
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityMild

ReversibilityReversible

Evidence6 citations

Nephron map

Vasculature / Endothelium

Proximal Tubule

Distal Tubule / Collecting Duct

Tubular Lumen

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Linvoseltamab has no intrinsic tubular, glomerular, or interstitial nephrotoxic mechanism. When AKI occurs it is hemodynamic/prerenal: T-cell activation drives cytokine release syndrome (IL-6, TNF, IFN-γ) causing vasodilation, capillary leak, hypotension, and renal hypoperfusion, sometimes compounded by fever/poor intake. In heavily pretreated myeloma, baseline cast nephropathy, hypercalcemia, and infection/sepsis add to the risk. Rapid plasma-cell lysis at initiation can cause tumor lysis syndrome with uric-acid/phosphate crystal nephropathy. Electrolyte shifts (hypokalemia, hypomagnesemia, hypophosphatemia) reflect critical-illness/supportive-care effects rather than a tubular wasting signature.

Clinical presentation

Most commonly an asymptomatic, modest creatinine rise during step-up/first full-dose CRS that resolves with hydration, antipyretics, and CRS management (tocilizumab ± steroids). Severe AKI is uncommon and almost always accompanies high-grade CRS, hypotension, or sepsis. Tumor lysis, when present, manifests early with hyperuricemia, hyperphosphatemia, hyperkalemia, and oliguria. Urinalysis is typically bland (prerenal pattern); muddy-brown casts suggest superimposed ATN from prolonged hypoperfusion.

Management

Manage the driver, not the drug. For CRS-associated AKI: treat CRS (tocilizumab, corticosteroids per grading), restore perfusion with isotonic fluids, and hold offending nephrotoxins. Provide TLS-directed care (aggressive hydration, rasburicase/allopurinol, electrolyte correction) when applicable. Most AKI is mild and resolves with supportive care; dose interruption is guided by CRS/overall toxicity rather than by a dedicated renal threshold. Persistent or worsening AKI warrants nephrology evaluation for superimposed ATN, cast nephropathy, or sepsis.Lesion-level management framework

Risk factors

Higher-grade cytokine release syndrome (Grade ≥2)
Pre-existing chronic kidney disease
High myeloma burden / risk of tumor lysis (elevated bone-marrow plasma cells, soluble BCMA)
Concurrent infection or sepsis
Volume depletion / hypotension
Light-chain cast nephropathy and hypercalcemia from underlying myeloma
Nephrotoxic co-medications and contrast exposure

Prevention

Mandatory step-up (split) dosing to blunt CRS severity
Pre-medication (corticosteroid, antihistamine, antipyretic) per label during step-up
Prompt tocilizumab ± steroids at CRS onset; prophylactic tocilizumab reduces CRS in real-world cohorts
Adequate hydration and avoidance of volume depletion around dosing
TLS prophylaxis (hydration, allopurinol/rasburicase) in high-burden disease
Treat/avoid concurrent infection; minimize nephrotoxin and contrast exposure
Optimize myeloma-related kidney burden (hypercalcemia, light chains)

Anticancer mechanism· how it treats cancer

Linvoseltamab is a fully human IgG4-based bispecific antibody that simultaneously binds B-cell maturation antigen (BCMA/TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that redirects polyclonal cytotoxic T cells to lyse myeloma cells independent of MHC restriction. Bridging triggers T-cell activation, proliferation, and release of perforin/granzyme and inflammatory cytokines, producing deep and durable myeloma responses.

Note · Renal data are extrapolated; linvoseltamab gained FDA accelerated approval in 2025 (Lynozyfic) and the LINKER-MM1 program did not surface a discrete nephrotoxicity signal, so the prerenal/CRS-hemodynamic classification is reasoned from drug class and immune-effector-therapy literature.

§04

Clinical depth

Renal dose adjustment

No renal dose adjustment is established. Pharmacokinetics of large IgG bispecific antibodies are not meaningfully governed by renal clearance, and the registrational program did not define renal cutoffs; patients with significant renal impairment were under-represented. Dose modification in practice is driven by CRS/ICANS and hematologic/infectious toxicity, not by creatinine.

Dialyzability & ESKD dosing

Not dialyzable. As a ~150 kDa IgG4-based bispecific antibody, linvoseltamab is eliminated by reticuloendothelial catabolism, not renal filtration, and is not removed by hemodialysis. No supplemental dosing around dialysis is indicated.

Differential diagnosis

Distinguish CRS-related hemodynamic/prerenal AKI (temporally locked to step-up dosing and fever/hypotension, bland urinalysis, rapid recovery) from: tumor lysis crystal nephropathy (early hyperuricemia/hyperphosphatemia); myeloma cast nephropathy or hypercalcemia from underlying disease; sepsis-associated ATN; and nephrotoxin/contrast injury. Unlike checkpoint inhibitors, linvoseltamab is not associated with acute interstitial nephritis, and unlike VEGF agents it does not cause hypertension/proteinuria/TMA.

Monitoring

Serial serum creatinine/eGFR through step-up dosing and the first cycles
CRS grading (temperature, blood pressure, oxygenation)
Tumor lysis labs (uric acid, phosphate, potassium, calcium, LDH) at initiation in high-burden disease
Electrolytes (K, Mg, PO4) during CRS and supportive care
Volume status and urine output
Infection surveillance given high infection rates in this class

Key trials & series

LINKER-MM1 (NCT03761108) — phase 1/2 first-in-human pivotal trial; 200 mg ORR 71%, ≥CR 52%, median DOR 29.4 months

Clinical pearls

A creatinine bump during step-up dosing usually means CRS/hypoperfusion; treat the CRS and rehydrate, and renal function typically recovers.
Not renally cleared and not dialyzable — no renal dose adjustment and no peri-dialysis dosing needed.
Front-load TLS prophylaxis in high-burden myeloma: deep, rapid plasma-cell lysis at initiation is the main crystal-nephropathy risk window.
No checkpoint-style AIN and no VEGF-style hypertension/proteinuria — the differential should center on hemodynamics, tumor lysis, and the patient's underlying myeloma kidney disease.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the BCMA×CD3 bispecific T-cell engager class.

Immune / Infusion

CRS, infusion reactions, irAEs, anaphylaxis

Cytokine release syndrome

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

ICANS / neurotoxicity

Hematologic

Cytopenias, thrombosis, TMA

Cytopenias, hypogammaglobulinemia

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2024–2025 · 6 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Guidelines & consensus· 19

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ASCOManagement of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineJ Clin Oncol 2021 · PMID 34724386Grade toxicities by ASTCT criteria; manage CRS with supportive care escalating to tocilizumab with or without corticosteroids, and manage moderate-to-severe ICANS with corticosteroids and supportive care given potential for rapid decline.TLS Expert PanelGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based reviewJ Clin Oncol 2008 · PMID 18509186Prevention is the best management: hydration plus prophylactic rasburicase for high-risk patients, hydration plus allopurinol or rasburicase for intermediate-risk, and monitoring for low-risk; for established TLS add aggressive hydration and diuresis plus allopurinol or rasburicase for hyperuricemia. Urinary alkalinization is NOT recommended.TLS Consensus PanelRecommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensusBr J Haematol 2010 · PMID 20331465Stratify each patient as low/intermediate/high TLS risk using tumor type, bulk/stage, proliferation rate, baseline laboratory TLS, and renal impairment/involvement, then match prophylaxis intensity (monitoring vs allopurinol vs rasburicase) to the assigned risk level.BCSHGuidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in HaematologyBr J Haematol 2015 · PMID 25876990Risk-adapted prophylaxis and management of TLS in haematological malignancy: hydration with allopurinol for lower-risk and rasburicase for high-risk patients, with monitoring of electrolytes and renal function to prevent and treat AKI.Cairo-BishopTumour lysis syndrome: new therapeutic strategies and classificationBr J Haematol 2004 · PMID 15384972Defines the Cairo-Bishop criteria distinguishing laboratory TLS (>=2 metabolic abnormalities: hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia within 3 days before to 7 days after therapy) from clinical TLS (laboratory TLS plus AKI, cardiac arrhythmia, or seizure), with a severity grading scheme adopted by subsequent guidelines.ASTCTASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsBiol Blood Marrow Transplant 2019 · PMID 30592986Grade CRS by fever, hypotension and hypoxia (grades 1-4) and grade ICANS using the ICE/encephalopathy score plus level of consciousness, seizures, motor findings and raised intracranial pressure/edema; this is the standard severity framework that triggers tocilizumab and corticosteroid escalation in CAR-T and bispecific antibody toxicity (the Lee 2019 consensus).

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Linvoseltamab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Odronextamab

Ordspono · Bispecific (CD20×CD3)

Profile

CD20×CD3 bispecific; tumor-lysis urate crystal nephropathy with CRS.

XTALPRELYTE

Moderate#1 · 82% phenotype match

Pirtobrutinib

Jaypirca · Non-covalent BTK inhibitor

Profile

2023 BTK inhibitor; tumor lysis risk.

XTALPRELYTE

Mild#2 · 81% phenotype match

Ibritumomab tiuxetan

Zevalin · Radioimmunotherapy (Y-90 anti-CD20)

Profile

Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.

PREXTALLYTE

Mild#3 · 79% phenotype match

Cladribine

Leustatin · Purine analog

Profile

Tumor lysis; high-dose nephrotoxicity.

XTALPRELYTE

Mild#4 · 78% phenotype match

Etoposide

Etopophos · Topoisomerase II inhibitor

Profile

Tumor lysis; renally cleared.

XTALPRELYTE

Mild#5 · 78% phenotype match

Hydroxyurea

Hydrea · Ribonucleotide reductase inhibitor

Profile

Tumor lysis in myeloproliferative disease.

XTALPRELYTE

Mild#6 · 78% phenotype match

Compare Linvoseltamab with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Bispecifics / T-cell engagers

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.